Asset profile
Human Serum Albumin/interferon alpha2b fusion protein
Biologic (subtype unspecified)
Evidence outlook
Completed readouts not yet graded
This drug has completed mid- or late-stage studies whose evidence has not yet been graded on this platform. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
46 competitors in this universe: 2 direct rivals (same mechanism and indication), 5 same-class, 39 same-indication; 31 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Human Serum Albumin / Interferon Alpha2b Fusion Protein: this drug | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Interferon Alfa-2b (Intron A) | Approved | — | Type I interferon receptor | ||
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Peginterferon Beta-1a (Plegridy) | Approved | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | ||
| Rebif (interferon Beta 1a) | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Adefovir Dipivoxil (Hepsera) | Approved | Small molecule | — | ||
| Entecavir (Baraclude) | Approved | Small molecule | — | ||
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Small molecule | — | ||
| Lamivudine (Epivir-HBV) | Approved | — | — | ||
| Telbivudine (Tyzeka) | Approved | — | — | ||
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | — | ||
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | ||
| Diluted I.V.-Hepabig inj(GC5103) | Phase 3 | Biologic (subtype unspecified) | — |
…and 31 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.